Cargando…

PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin

The hepatoprotective properties of silibinin, as well its therapeutic potential as an anticancer and chemo-preventive agent, have failed to progress towards clinical development and commercialization due to this material’s unfavorable pharmacokinetics and physicochemical properties, low aqueous solu...

Descripción completa

Detalles Bibliográficos
Autores principales: Budurova, Desislava, Momekova, Denitsa, Momekov, Georgi, Shestakova, Pavletta, Penchev, Hristo, Rangelov, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709077/
https://www.ncbi.nlm.nih.gov/pubmed/34959307
http://dx.doi.org/10.3390/pharmaceutics13122025
_version_ 1784622845280649216
author Budurova, Desislava
Momekova, Denitsa
Momekov, Georgi
Shestakova, Pavletta
Penchev, Hristo
Rangelov, Stanislav
author_facet Budurova, Desislava
Momekova, Denitsa
Momekov, Georgi
Shestakova, Pavletta
Penchev, Hristo
Rangelov, Stanislav
author_sort Budurova, Desislava
collection PubMed
description The hepatoprotective properties of silibinin, as well its therapeutic potential as an anticancer and chemo-preventive agent, have failed to progress towards clinical development and commercialization due to this material’s unfavorable pharmacokinetics and physicochemical properties, low aqueous solubility, and chemical instability. The present contribution is focused on the feasibility of using PEGylated calixarene, in particular polyoxyethylene-derivatized tert-octylcalix[8]arene, to prepare various platforms for the delivery of silibinin, such as inclusion complexes and supramolecular aggregates thereof. The inclusion complex is characterized by various instrumental methods. At concentrations exceeding the critical micellization concentration of PEGylated calixarene, the tremendous solubility increment of silibinin is attributed to the additional solubilization and hydrophobic non-covalent interactions of the drug with supramolecular aggregates. PEG-modified tert-octylcalix[8]arenes, used as drug delivery carriers for silibinin, were additionally investigated for cytotoxicity against human tumor cell lines.
format Online
Article
Text
id pubmed-8709077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87090772021-12-25 PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin Budurova, Desislava Momekova, Denitsa Momekov, Georgi Shestakova, Pavletta Penchev, Hristo Rangelov, Stanislav Pharmaceutics Article The hepatoprotective properties of silibinin, as well its therapeutic potential as an anticancer and chemo-preventive agent, have failed to progress towards clinical development and commercialization due to this material’s unfavorable pharmacokinetics and physicochemical properties, low aqueous solubility, and chemical instability. The present contribution is focused on the feasibility of using PEGylated calixarene, in particular polyoxyethylene-derivatized tert-octylcalix[8]arene, to prepare various platforms for the delivery of silibinin, such as inclusion complexes and supramolecular aggregates thereof. The inclusion complex is characterized by various instrumental methods. At concentrations exceeding the critical micellization concentration of PEGylated calixarene, the tremendous solubility increment of silibinin is attributed to the additional solubilization and hydrophobic non-covalent interactions of the drug with supramolecular aggregates. PEG-modified tert-octylcalix[8]arenes, used as drug delivery carriers for silibinin, were additionally investigated for cytotoxicity against human tumor cell lines. MDPI 2021-11-27 /pmc/articles/PMC8709077/ /pubmed/34959307 http://dx.doi.org/10.3390/pharmaceutics13122025 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Budurova, Desislava
Momekova, Denitsa
Momekov, Georgi
Shestakova, Pavletta
Penchev, Hristo
Rangelov, Stanislav
PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title_full PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title_fullStr PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title_full_unstemmed PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title_short PEG-Modified tert-Octylcalix[8]arenes as Drug Delivery Nanocarriers of Silibinin
title_sort peg-modified tert-octylcalix[8]arenes as drug delivery nanocarriers of silibinin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709077/
https://www.ncbi.nlm.nih.gov/pubmed/34959307
http://dx.doi.org/10.3390/pharmaceutics13122025
work_keys_str_mv AT budurovadesislava pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin
AT momekovadenitsa pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin
AT momekovgeorgi pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin
AT shestakovapavletta pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin
AT penchevhristo pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin
AT rangelovstanislav pegmodifiedtertoctylcalix8arenesasdrugdeliverynanocarriersofsilibinin